The Defense Biological Product Assurance Office (DBPAO), previously known as the Critical Reagents Program (CRP), is conducting market research on capabilities of commercial partners to provide reagent services for select biological threat agents. [Read more]
The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) equipment or life science research of interest for potential applications [Read more]
The U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which are adaptable to incorporating known antigens for use as a prophylaxis countermeasure [Read more]
The U.S. Department of Defense is seeking information from organizations on their capability to support advanced development of human butyrylcholinesterase (HuBChE) as a medical countermeasure. Overseen by the Joint Product Manager – [Read more]
Battelle was recently selected as a qualifying contractor to bid for chemical and biological defense work for the next five years under the $900 million Joint Enterprise Contracted Logistics and Services Support [Read more]
Colorado State University’s Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded a 10-month, $4.6 million contract to help develop and manufacture new vaccines to fight Western, Eastern and Venezuelan Equine [Read more]
The Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) has awarded a $900,000,000 indefinite-delivery/indefinite-quantity, multiple award task order contract for logistics and service support to: Aktarius LLC, Panama City, Florida [Read more]
An industry day will be hosted in Stafford, Virginia on January 26, 2016 in support of the Department of Defense Joint General Purpose Decontaminant for Hardened Military Equipment (JGPD-HME) acquisition effort. The [Read more]
The U.S. Department of Defense’s Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) will host an Industry Day on 2 Nov. 2015 in Fairfield, NJ. JPM-MCS is a DoD program within the Joint Program [Read more]
The DoD Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office has a requirement to develop and deliver FDA licensed butyrylcholinesterase (BChE). BChE is a bioscavenger prophylactic countermeasure against organophosphate nerve [Read more]
© 2017 Global Biodefense